openPR Logo
Press release

Gemigliptin Market Study Analysis with Forecast to 2031

02-12-2024 09:26 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Insightace analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And Industry Analysis 2031"

The Gemigliptin Market Size is valued at USD 1.66 billion in 2022 and is predicted to reach USD 2.65 billion by the year 2031 at a 5.5% CAGR during the forecast period for 2023-2031.

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2031

Gemigliptin is an oral diabetes medicine that belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is used to treat type 2 diabetes, a chronic metabolic condition marked by insulin resistance and high blood sugar levels. Gemigliptin works by inhibiting the enzyme DPP-4, which is in charge of the breakdown of incretin hormones, which regulate blood glucose levels.

Gemigliptin enhances the levels of these hormones by blocking DPP-4, resulting in improved insulin secretion and decreased glucose synthesis by the liver. Due the rising incidence of diabetes worldwide and the increasing acceptance of efficient oral antidiabetic medications, the global Gemigliptin market has been steadily growing. Pharmaceutical companies continue investing in R&D to improve existing pharmaceuticals and discover novel treatments. This continuous innovation could lead to the release of newer and more advanced DPP-4 inhibitors, thereby growing the market. Gemigliptin is becoming more popular as a safer and more convenient diabetes treatment choice.

List of Prominent Players in the Gemigliptin Market:
• LG Chem
• Hanmi Pharmaceutical Co., Ltd.
• Boryung Pharmaceutical Co., Ltd.
• Novartis AG
• EirGenix, Inc.
• Biocon Limited
• G.L. Pharma GmbH
• Daewoong Pharmaceutical Co., Ltd.
• Sandoz International GmbH
• Boryung Pharmaceutical Co., Ltd.
• VHB Life Sciences Limited
• HanAll Biopharma
• Taiba Healthcare
• Huons Co., Ltd.
• Dong-A ST Co., Ltd

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2031

Market Dynamics:
Drivers-
Diabetes is becoming more common worldwide at an alarming rate, affecting millions of people. Diabetes is becoming a significant public health concern, and there is an increasing demand for effective and safe antidiabetic medications like Gemigliptin to control the condition and improve patient outcomes. Furthermore, oral antidiabetic drugs are gradually replacing insulin injections due to their comfort and ease of administration. Gemigliptin is an oral antidiabetic medicine favored by patients who are not insulin-dependent, contributing to its market growth.

Challenges:
Gemigliptin faces significant competition from other types of diabetes drugs, such as metformin, sulfonylureas, and SGLT-2 inhibitors. Established pharmaceuticals with a lengthy history of usage and proven performance may hinder the market penetration of newer therapies like Gemigliptin. Patents on Gemigliptin and other DPP-4 inhibitors may expire, allowing generic copies to enter the market. This can lead to pricing challenges and limited revenue possibilities for branded Gemigliptin medicines. In addition, As with any medicine, safety issues might influence patient and physician opinions of Gemigliptin. Although the safety profile of Gemigliptin is generally well-established, continued monitoring and any safety alerts may limit its uptake and use.

Regional Trends:
The North America Gemigliptin Market is expected to report a major market share and is projected to grow at a high CAGR shortly. Diabetes, particularly type 2 diabetes, is a significant driver of the Gemigliptin market in North America. Diabetes has become more prevalent in the region due to factors such as sedentary lifestyles, bad diets, and obesity. Because of North America's well-developed healthcare infrastructure, drugs such as Gemigliptin are widely available. Healthcare providers have the resources necessary to diagnose, treat, and control diabetes properly. Diabetes prevalence, particularly type 2 diabetes, has risen dramatically in Asia. Changes have aided this rise in lifestyle, urbanization, and food preferences. The Asia Pacific area has a sizable generics market, and the advent of generic versions of Gemigliptin or other DPP-4 inhibitors could have an impact on market dynamics.

Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/2031

Recent Developments:
• In March 2023, Sanofi introduced a new fixed-dose combination medication, including gemigliptin and saxagliptin (Jentadueto XR), in the United States. This medicine is indicated for treating individuals with type 2 diabetes mellitus who are not effectively controlled with diet and exercise alone or with other diabetes drugs.

Segmentation of Gemigliptin Market-
By Type of Drug-
• Gemigliptin Monotherapy
• Gemigliptin Combination Therapy)
By Dosage Form-
• Gemigliptin Tablets
• Gemigliptin Injectable
By Distribution Channel-
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End-User-
• Hospitals
• Clinics and Outpatient Facilities
• Homecare Settings
By Application-
• Type 2 diabetes
• Prediabetes
By Patient Demographics-
• Adult Population
• Geriatric Population
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

For More Information: https://www.insightaceanalytic.com/report/gemigliptin-market/2031

Corporate Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
loaction icon
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
email iconinfo@insightaceanalytic.com
call icon
North America:
+1 551 226 6109
Asia:
+91 79 72967118

Contact Us:
Dhanraj Zurange
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gemigliptin Market Study Analysis with Forecast to 2031 here

News-ID: 3380765 • Views:

More Releases from Insightace analytic

Digital Pathology Market Report- Expansive Coverage on the Profit Sources
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031" The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031 "Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by
Digital Diabetes Management Market Report on the Untapped Growth Opportunities in the Industry
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 2031
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031" The Global Data Center Liquid Cooling Market is estimated

All 5 Releases


More Releases for Gemigliptin

Gemigliptin Market Regional Outlook, Leading Companies, Product, End Users for t …
The global Gemigliptin market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Gemigliptin market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Gemigliptin Market.
Gemigliptin Market Regional Growth Drivers, Opportunities and Trends 2021-2027| …
The Gemigliptin market report gives an itemized examination of worldwide market size, territorial and nation level market size, division market development, piece of the pie, cutthroat Landscape, deals investigation, effect of homegrown and worldwide market players, esteem chain streamlining, exchange guidelines, late turns of events, openings examination, vital market development examination, item dispatches, region commercial center extending, and mechanical advancements. The focuses that are talked about inside the report are the
Gemigliptin Market Regional Growth Drivers, Opportunities and Trends 2021-2027| …
Gemigliptin (rINN), sold under the brand name Zemiglo, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) class of drugs. Glucose lowering effects of DPP-4 inhibitors are mainly mediated by GLP-1 and gastric inhibitory polypeptide (GIP) incretin hormones which are inactivated by DPP-4.[medical citation needed] Gemigliptin was initially developed solely by LG Life Sciences. In 2010, Double-Crane Pharmaceutical Co. (DCPC) joined with LGLS to co-develop the
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share, Impressive Industr …
The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is sectioned on the basis of drug type. The market is sectioned as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the global dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are
Gemigliptin Market global outlook and forecast 2021 -2027|Sanofi,LG Chem
The Global Gemigliptin Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Gemigliptin makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements. The report likewise spins around the most powerful factors of
Gemigliptin L-tartrate sesquihydrate Market global outlook and forecast 2021 -20 …
The Global Gemigliptin L-tartrate sesquihydrate Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Gemigliptin L-tartrate sesquihydrate makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements. The report likewise spins around the